Continuous subcutaneous terbutaline infusion for treatment of preterm labor

Citation
Continuous subcutaneous terbutaline infusion for treatment of preterm labor. Lansdale: HAYES, Inc., 2010

Authors' objectives
Terbutaline is used for the prevention of preterm birth. Typically, treatment for women with preterm uterine contractions is started with intensive tocolytic therapy. When contractions have been reduced to less than 4 to 6 per hour, terbutaline is administered as a continuous subcutaneous infusion to prevent the reinstatement of premature labor and preterm birth. Depending on the treatment protocol, terbutaline is infused with a pump at 0.05 mg to 0.75 mg per hour with boluses of 0.25 mg at regular intervals or as needed. Average duration of infusion ranges from 4 weeks to 7 weeks; however, some patients may require more than 10 weeks of infusion.

Timeliness warning
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.

Project page URL
http://www.hayesinc.com

Indexing Status
Subject indexing assigned by CRD

MeSH
Adrenergic beta-Agonists; Females; Infusions, Subcutaneous; Obstetric Labor, Premature; Pregnancy; Terbutaline; Tocolytic Agents

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: mwinkler@hayesinc.com

AccessionNumber
32010001383

Date abstract record published
03/11/2010